Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Death/hospitalization 71% Improvement Relative Risk Death/hospitalization (b) 70% Recovery time 29% Recovery time (b) 29% c19early.com/r Regeneron et al. Casirivimab/i.. for COVID-19 RCT EARLY Favors casirivimab/im.. Favors control
Regeneron, 2,696 patient casirivimab/imdevimab early treatment RCT: 71% lower combined mortality/hospitalization [p<0.0001] and 29% faster recovery [p=0.0001] https://c19p.org/regeneron3
copied to clipboard
New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
Regeneron Press Release (Preprint)
23 Mar 2021    Source   PDF   Share   Tweet
Press release for new phase III data showing lower hospitalization/mortality, and faster symptom resolution among the subset of patients with at least one risk factor.
Some variants may escape antibodies [cell.com].
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan].
risk of death/hospitalization, 71.3% lower, RR 0.29, p < 0.001, treatment 18 of 1,355 (1.3%), control 62 of 1,341 (4.6%), NNT 30, 2,400mg IV, >=1 risk factor.
risk of death/hospitalization, 70.4% lower, RR 0.30, p = 0.003, treatment 7 of 736 (1.0%), control 24 of 748 (3.2%), NNT 44, 1,200mg IV, >=1 risk factor.
recovery time, 28.6% lower, relative time 0.71, p < 0.001, treatment 1,355, control 1,341, 2,400mg IV, >=1 risk factor.
recovery time, 28.6% lower, relative time 0.71, p < 0.001, treatment 736, control 748, 1,200mg IV, >=1 risk factor.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Regeneron et al., 23 Mar 2021, Randomized Controlled Trial, USA, preprint, 1 author.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit